Seegene Unveils the World's First Fully Autonomous PCR Automation at ADLM 2025

Seegene Unveils Revolutionary Fully Autonomous PCR Automation at ADLM 2025

At the annual ADLM 2025 (Association for Diagnostic and Laboratory Medicine) conference, held in Chicago from July 28 to 31, Seegene Inc., a world leader in molecular diagnostics, made headlines by unveiling CURECA™, the world’s first fully autonomous PCR testing automation system. This innovative technology promises to radically enhance the efficiency and accuracy of diagnostic processes, shifting the paradigm in global healthcare.

The CURECA™ System: A Game Changer in PCR Testing

CURECA™ is an all-encompassing automation system that manages the complete PCR testing workflow—from specimen storage and pretreatment to nucleic acid extraction and result analysis—without human intervention. Designed for continuous operation 24/7, CURECA™ effectively minimizes human error, leading to significantly more consistent and reliable test outcomes.

One of the standout features of CURECA™ is its fully automated preparation module, which has conquered one of the most labor-intensive and error-prone stages of laboratory workflows. Traditional pre-treatment has been a substantial challenge, particularly with various sample types such as urine, blood, sputum, and stool.

Laboratory technicians traditionally spend countless hours performing repetitive tasks, and variances in individual skill levels can result in inconsistent results. The high viscosity and particle presence in stool samples has posed significant barriers to automation, necessitating intensive manual handling. CURECA™ is the first system to fully automate pre-treatment across all major sample types, including stool, thereby overcoming long-standing obstacles in laboratory operations. This innovation not only reduces the workload but also expands sample processing capacity, enhancing operational efficiency and cost-effectiveness.

The introduction of CURECA™ also redefines laboratory personnel roles, transitioning them from manual tasks to higher-level responsibilities like data analysis and clinical interpretation. This shift allows laboratories to optimize the potential of their workforce in high-volume testing environments, ensuring high-quality and sustainable testing outcomes.

Furthermore, the preparation module of CURECA™ is adaptable beyond PCR diagnostics, enabling pre-treatment for other fields, including clinical chemistry and immunoassays, marking a significant step toward comprehensive automation in diagnostics.

STAgora™: Real-time Global Data Integration and Analysis

Alongside CURECA™, Seegene introduced STAgora™, a cutting-edge statistical platform that collects and analyzes real-time PCR diagnostic data, aiding clinical decision-making. By aggregating data from tests uploaded by hospitals around the globe, STAgora™ provides a consolidated view of regional infection trends, hospital positivity rates, and co-infection patterns.

The platform offers more than 40 statistics tools specifically designed to support clinical practices. Health professionals can compare individual test results with local and regional epidemiological data, facilitating more precise and data-driven treatment strategies. By enabling the evaluation of infection trends at both individual and community levels, STAgora™ enhances the speed and accuracy of diagnostics and treatment planning.

With its comprehensive analytical capabilities, STAgora™ is poised to become an indispensable tool for clinical decision-making, promising a brighter future for personalized healthcare.

Global Expansion and Strategic Partnerships

During ADLM 2025, Seegene aims to broaden access to CURECA™ and STAgora™ through early pilot experiences and new global partnerships. Earlier this year, CURECA™ attracted significant attention at ESCMID Global 2025, a leading European conference focused on clinical microbiology and infectious diseases.

To boost its R&D and manufacturing capabilities in the United States, Seegene has established local subsidiaries, including Seegene Technologies and Seegene CURECA.

Daniel Shin, Executive Vice President and Global Head of Sales and Marketing at Seegene, stated, “CURECA™ and STAgora™ are not just diagnostic tools; they represent a new global standard that will redefine clinical diagnostics worldwide. We remain committed to sharing our technological assets honed over years and driving fundamental innovation across the global diagnostics ecosystem.”

Conclusion

Seegene’s CURECA™ and STAgora™ present groundbreaking innovations that are poised to transform the landscape of diagnostic testing. As the world moves towards more automated and efficient healthcare solutions, these advancements signify a monumental leap forward in the quest for reliable and timely diagnostics. For more information, visit Seegene.com and follow them on LinkedIn.